Katherine Liau

2.5k total citations · 1 hit paper
36 papers, 2.0k citations indexed

About

Katherine Liau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Katherine Liau has authored 36 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Katherine Liau's work include Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Renal cell carcinoma treatment (8 papers). Katherine Liau is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Renal cell carcinoma treatment (8 papers). Katherine Liau collaborates with scholars based in United States, Germany and United Kingdom. Katherine Liau's co-authors include Paul Bycott, Sinil Kim, Olivier Rixe, Everett E. Vokes, David R. Shalinsky, Peter C. Trask, Roger B. Cohen, Ezra E.W. Cohen, Lee S. Rosen and Madeleine Kane and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Katherine Liau

35 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

2008 494 citations Ezra E.W. Cohen, Lee S. Rosen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Katherine Liau

Since Specialization

Citations

This map shows the geographic impact of Katherine Liau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Liau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Liau more than expected).

Fields of papers citing papers by Katherine Liau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Liau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Liau. The network helps show where Katherine Liau may publish in the future.

Co-authorship network of co-authors of Katherine Liau

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Liau. A scholar is included among the top collaborators of Katherine Liau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Liau. Katherine Liau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD) 2023 ·Expert Opinion on Biological Therapy ·Bernd Bokemeyer, Tibor Hlavatý, Matthieu Allez, (unknown), (unknown), (unknown), Heather Fowler, Markus Mueller, Katherine Liau, Javier P. Gisbert	4
2	1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine 2021 ·Annals of Oncology ·Stephen J. Thomas, John L. Perez, Stephen Lockhart, Seetharaman Hariharan, Nicholas Kitchin, R.A. Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Uğur Şahin, Xia Xu, Samuel S. Dychter, Cuncun Lu, Teresa Gentile, William C. Gruber	9
3	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial 2021 ·Vaccine ·Stephen J. Thomas, John L. Perez, Stephen Lockhart, Hariharan Subramanian, Nicholas Kitchin, Ruth Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Uğur Şahin, Xia Xu, Kenneth Koury, Samuel S. Dychter, (unknown), Teresa Gentile, William C. Gruber	38
4	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study 2019 ·BioDrugs ·Niels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, (unknown), Angel H. Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara	38
5	Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials 2018 ·Blood ·Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan O’Brien, Matthias Stelljes, Tao Wang, Katherine Liau, Kevin T. Nguyen, Barbara Sleight, Erik Vandendries, (unknown), Alexander Laird, Anjali S. Advani	3
6	A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. 2018 ·Journal of Clinical Oncology ·Mark A. Socinski, Joachim von Pawel, Kazuo Kasahara, Igor Bondarenko, Konstantinos Syrigos, Vladimir Vladimirov, Maciej Bryl, (unknown), (unknown), Fiona Hilton, Katherine Liau, Roy S. Herbst	2
7	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma 2011 ·Clinical Cancer Research ·John P. Fruehauf, Jose Lutzky, David H. McDermott, Charles K. Brown, Jean‐Baptiste Méric, Brad Rosbrook, David R. Shalinsky, Katherine Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe	93
8	Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial 2011 ·Clinical Breast Cancer ·Nicholas J. Robert, Mansoor N. Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Mehmet S Copur, Adam Brufsky, Susan Minton, Jeffrey K. Giguere, John W. Smith, Paul Richards, Diana Gernhardt, Xin Huang, Katherine Liau, Kenneth A. Kern, Jason J. Davis	94
9	A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors 2010 ·Journal of Clinical Oncology ·Christopher J. Sweeney, E. Gabriela Chiorean, Claire F. Verschraegen, (unknown), Suzanne F. Jones, Melanie Royce, L. Tye, Katherine Liau, Akintunde Bello, Richard C. Chao, Howard A. Burris	41
10	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study breakdown → 2008 ·Journal of Clinical Oncology ·Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes, Merrill S. Kies, Arlene A. Forastiere, Francis P. Worden, Madeleine Kane, Eric J. Sherman, Sinil Kim, Paul Bycott, Michael A. Tortorici, David R. Shalinsky, Katherine Liau, Roger B. Cohen	494
11	Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study 2008 ·The Lancet ·Jean‐Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Carlo Barone, Richard Létourneau, Emilio Bajetta, Yazdi K. Pithavala, Paul Bycott, Peter C. Trask, Katherine Liau, Alejandro D. Ricart, Sinil Kim, Olivier Rixe	204
12	Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib 2008 ·Acta Oncologica ·Peter C. Trask, Andrew G. Bushmakin, Joseph C. Cappelleri, Paul Bycott, Katherine Liau, Sinil Kim	18
13	Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors 2007 ·Molecular Cancer Therapeutics ·Roger B. Cohen, Mark Kozloff, (unknown), Yazdi K. Pithavala, Michael A. Tortorici, Katherine Liau, Jamal Tarazi, Anthony J. Olszanski	1
14	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study 2007 ·The Lancet Oncology ·Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson, George Wilding, Gary R. Hudes, O. Bolte, Robert J. Motzer, Paul Bycott, Katherine Liau, James L. Freddo, Peter C. Trask, Sinil Kim, Brian I. Rini	356
15	Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial 2007 ·Clinical Lung Cancer ·Joan H. Schiller, Joachim von Pawel, Timothy Larson, S-H.I. Ou, Steven Limentani, Alan B. Sandler, Everett E. Vokes, (unknown), Katherine Liau, Paul Bycott	1
16	A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component 2007 ·Journal of Clinical Oncology ·Jean‐Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Yazdi K. Pithavala, Paul Bycott, Katherine Liau, (unknown), Olivier Rixe	14
17	5507 ORAL A phase 2 study of axitinib (AG-013736; AG) in patients (pts) with advanced thyroid cancers 2007 ·European Journal of Cancer Supplements ·Ezra E.W. Cohen, E. Vokes, (unknown), M.S. Kies, A. Forastiere, Frank Worden, (unknown), Katherine Liau, David R. Shalinsky, Romain Cohen	1
18	A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) 2007 ·Journal of Clinical Oncology ·Hope S. Rugo, Alison Stopeck, Anil A. Joy, Stephanie Chan, Savita Verma, Aňa Lluch, Katherine Liau, (unknown), Paul Bycott, Denis Soulières	35
19	A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer 2006 ·Journal of Clinical Oncology ·(unknown), Lee S. Rosen, Ezra E.W. Cohen, Roger B. Cohen, A. Forastiere, Ana Silva, Katherine Liau, Robert Archer, Paul Bycott, Everett E. Vokes	12
20	137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors 2004 ·European Journal of Cancer Supplements ·A. W. Tolcher, James J. O’Leary, Johann S. de Bono, Kelly L. Molpus, (unknown), (unknown), Katherine Liau, D A Noe, Diane Healey, Mark S. Huberman	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact